RABINOWITZ DANIEL sold $485K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,887 shares of Natera, Inc. (NTRA) at an average of $257.08 ($254.07–$260.49, $0.49M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not change Natera’s business outlook based on the information provided.

02

Market read

Insider selling under a 10b5-1 plan is generally low-signal; any trading impact is likely limited unless corroborated by other negative catalysts.

03

What to watch

Traders should check whether there were concurrent insider buys/sales by other executives and whether the sale size is unusual relative to prior Form 4 activity.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering sales on 2026-07-27 to 2026-07-28.

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz, Chief Legal Officer, sold 1,887 shares in open-market trades under a 10b5-1 plan at $254.07 to $260.49.

Expected impact

Likely limited, short-lived impact unless paired with other negative company news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by an officer; it does not provide new operational, financial, or regulatory information.

Market effects

Minimal; insider sale in a single biotech/health-tech name does not reset sector fundamentals.

Minimal; US-listed filing with no broader macro/regional catalyst.

Minimal; no international transaction or regulatory action described.

Counterpoint

Because the trades are explicitly under a pre-arranged 10b5-1 plan, the sale may reflect diversification or liquidity needs rather than a bearish view.

Key entities

  • Natera, Inc.

    US-listed company whose officer insider sale is disclosed via SEC Form 4.

  • Daniel Rabinowitz

    Chief Legal Officer who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.